bluebird bio isn't soaring so high on 03 June, after the company announced that Celgene has opted to hand back all of the work the companies were doing together and only move forward with one program.
The Wall Street darling tried to smooth over the negative news during an aftermarket conference call with investors, saying it would "take years to play out" and that exclusivity with a single partner is "not practical
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?